W
WLC
Entrepreneur

Biograph and the 'Diagnostic Day': Why Luxury Is No Longer the Product

An inside look at Biograph: 6 hours, 30+ tests, and 1,000+ data points. The clinical question isn't 'what do you measure' — it's what decisions you change with the data.

biograph diagnostics executive health clinics

Clinical longevity is creating a new format: the ‘diagnostic day’.

Source: Entrepreneur

In an Entrepreneur article, the author recounts their experience at Biograph (Manhattan) undergoing its core assessment: a six-hour visit with a testing package that, according to the piece, accumulates “30+ assessments” and “1,000+ data points.” The packaging is boutique. The underlying theme is more serious: diagnostics are becoming a product.

What the Experience Describes (Concrete Signals)

The article emphasizes three elements that recur across premium clinics:

  • Environment: private rooms, hotel-like treatment, calm aesthetics (reduces anxiety and increases conversion).
  • Testing battery: a “one-day workup” with advanced diagnostics.
  • Post-visit delivery: a 1:1 review with a physician and a “risk profile” synthesizing results.

In other words: this is not a traditional checkup. It’s an “event.”

What These Packages Include (and at What Price)

Comprehensive longevity assessments like Biograph’s typically include a set of tests that, individually, have solid clinical backing:

  • Full-body MRI (detection of masses, vascular anomalies, incidental findings)
  • DEXA scan (bone density and body composition: fat mass, lean mass, distribution)
  • Coronary calcium score (CAC) (an established predictor of 10-year cardiovascular risk)
  • VO2max (cardiorespiratory fitness; one of the best predictors of all-cause mortality)
  • Extended blood panels (100+ biomarkers: advanced lipid, inflammatory, hormonal, metabolic, genomic)
  • Cognitive and neuromuscular function tests

As for pricing, the market spectrum is wide. Fountain Life charges approximately $19,500 for its full annual assessment. Biograph sits in a similar range for its premium Manhattan package. At the other end, Forward offers a membership model at ~$150/month with access to basic diagnostics and app-based follow-up, but without advanced imaging. Clinics like LifeWellMD in Florida are positioning segmented assessments at intermediate price points.

The Question That Matters: What Changes in the Patient’s Life?

Precision medicine is not about measuring more. It’s about making better decisions.

The typical risk of this format is falling into data theater:

  • more tests → more incidental findings
  • more findings → more follow-up tests
  • more tests → more cost, more anxiety

…without necessarily translating into better health.

Does Early Detection Change Outcomes in This Demographic?

The evidence on aggressive screening in asymptomatic adults is nuanced. The CAC score has strong backing for reclassifying cardiovascular risk in intermediate-risk individuals (ACC/AHA). VO2max is a robust mortality predictor with clear interventions (exercise). However, full-body MRI in asymptomatic populations continues to generate debate: a Prenuvo study (one of the most visible operators) reported clinically significant findings in approximately 14% of cases, but critics point to false positive rates and cascading unnecessary tests.

The serious version of this model requires that each diagnostic block comes with:

  1. Indication criteria (who needs it and who doesn’t)
  2. Action plan (what changes if the result is A/B/C)
  3. Follow-up (what we repeat, when, and why)

Diagnostics as a Service: The Industry Is Converging

What’s relevant about Biograph is not that it exists. It’s that it represents a pattern:

  • preventive medicine packaged as a membership
  • advanced diagnostics as the “entry point”
  • and continuity (coaching, habits, retesting) as retention

This looks more like a subscription product than a medical consultation. And the market will continue debating whether that productization is the future of prevention or just packaged luxury.

The difference will come down to who converts data into decisions that actually extend healthspan — and who merely sells the illusion of control through a 50-page report that no one implements. In a sector where the diagnostic offering multiplies every quarter, competitive advantage won’t lie in the machine, but in the clinical judgment of whoever interprets the results and designs the subsequent action plan.

Primary source: Entrepreneur (Source: Entrepreneur, 2026).